Target intelligence / Profile preview

Yttrium-90-labeled microsphere-targeted tumor tissue

Molecular classification
Other
01

Overview

The phrase "Tumor tissue via local beta radiation emission from yttrium‑90‑labeled microspheres" does not refer to a specific molecular or cellular therapeutic target such as a receptor, enzyme, or transporter. Instead, it describes the **anatomical and pathological site**—tumor tissue—being treated by a physical process involving radioactive medical devices. In this therapy (commonly called selective internal radiation therapy [SIRT] or radioembolization), microscopic beads loaded with the radioactive isotope yttrium‑90 are delivered via catheter into arteries supplying the tumor. The beads become lodged in small blood vessels within the tumor; there they emit beta radiation over about two weeks. This localized irradiation destroys nearby cancer cells while minimizing exposure to healthy surrounding tissues due to limited penetration of beta particles. The approach is primarily used for unresectable primary and metastatic liver cancers. This entry is **not a canonical druggable molecular target** but rather an anatomical treatment strategy using device-based delivery of local radiotherapy. Once trapped in the tumour’s microvasculature, the microspheres emit beta radiation that travels a limited distance—generally a few millimetres—destroying nearby tumour cells while sparing healthy liver tissue further away. The glass microspheres penetrate the tumor arteriolar capillaries where they emit lethal beta radiation that is localised to the surrounding tumor tissue. Because this "target" refers only to **tumor location** rather than any specific molecule or protein expressed by those tumors, it should be flagged as incorrect for structured molecular targeting purposes.

Other names
Yttrium-90 radioembolization targetSIRT targetY-90 microsphere tumor siteRadioembolization target tissue
02

Mechanism of action

Local emission of beta radiation from yttrium‑90 within the tumor vasculature causes lethal DNA damage and cell death in nearby tumor cells while sparing most normal tissue due to limited penetration distance

03

Biological functions

Other
04

Disease associations

CancerLiver cancerMetastatic liver tumorsHepatocellular carcinomaColorectal cancer metastasis to liver
05

Safety considerations

Non-target embolization (microspheres lodging in non-tumor tissues such as stomach or lungs)Radiation-induced liver diseasePostembolization syndrome (fatigue, flu-like symptoms)
06

Interacting drugs

Yttrium-90-labeled resin microspheres (e.g., SIR-Spheres)

2 more in the full profile.

Beyond the preview

Go deeper on Yttrium-90-labeled microsphere-targeted tumor tissue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yttrium-90-labeled microsphere-targeted tumor tissue.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call